TAFA3: A Potential Drug Target for Cancer (G284467)

Target Name: TAFA3

NCBI ID: G284467

TAFA3

TAFA3: A Potential Drug Target for Cancer

TAFA3: A Potential Drug Target and Biomarker for Family with Sequence Similarity 19 Member A3 and C-C Motif Chemoattractant-Like

Abstract:

Tumor antigens (TA) are molecules that have the potential to trigger an immune response against cancer cells.TAFA3, a 19-member family member known as the chemokine-like protein A3, has been identified as a potential drug target and biomarker for cancer. This protein is characterized by a C-C motif and a family-specific 尾-sheet that is similar to that of the chemokine intercellular factor IP3. The C-C motif plays a crucial role in the regulation of IP3 and theTAFA3's ability to induce cell signaling pathways. Furthermore, the A3 subunit has been shown to interact with various cytokines, including PD-L1, which may contribute to its potential as a biomarker for cancer.

Introduction:

Cancer is a leading cause of death worldwide, and its development and progression are influenced by various factors, including genetic mutations, environment, and immune responses.One of the immune responses that mounts against cancer cells is the production of tumor antigens (TA).TA antigens are molecules that have the potential to stimulate an immune response against cancer cells, including T cells, which recognize and respond to cancer antigens. The identification of potential drug targets and biomarkers for cancer has the potential to improve treatment outcomes and increase survival rates.

TAFA3: A Characterization of a Family with Sequence Similarity 19 Member A3 and C-C Motif Chemoattractant-Like

TAFA3 is a 19-member family member that is characterized by a C-C motif and a family-specific 尾-sheet that is similar to that of the chemokine intercellular factor IP3. The C-C motif plays a crucial role in the regulation of IP3 and theTAFA3's ability to induce cell signaling pathways. The A3 subunit has been shown to interact with various cytokines, including PD-L1, which may contribute to its potential as a biomarker for cancer.

The TAFA3 gene was identified and its expression was verified in various cancer cell lines and human tissues. The gene has been shown to be expressed in a variety of tissues, including lung, breast, colon, and liver cancer, as well as in the primary human cervical epithelial cells. The gene has also been shown to be expressed in various normal tissues, including the skin, heart, and brain.

TAFA3 has been shown to induce cell signaling pathways, including the production of chemokines and the upregulation of various cytokines. The A3 subunit has been shown to interact with several cytokines, including PD-L1, which is a negative regulator of the immune response. The interaction between TAFA3 and PD-L1 has been shown to contribute to the tumor-promoting effects of TAFA3.

TAFA3 has also been shown to contribute to the development of cancer. For example, TAFA3 has been shown to promote the migration and invasion of cancer cells. The A3 subunit has also been shown to contribute to the development of cancer cell stemness.

Potential Drug Target:

TAFA3's potential as a drug target is due to its unique structure and the various functions it has been shown to play in cancer development. One potential target for TAFA3 is the PD-L1 pathway. PD-L1 is a negative regulator of the immune response and has been shown to play a crucial role in the development of cancer. The interaction between TAFA3 and PD-L1 has been shown to contribute to the tumor-promoting effects of TAFA3.

Another potential target for TAFA3 is the TGF-β pathway. TGF-β is a cytokine that plays a crucial role in

Protein Name: TAFA Chemokine Like Family Member 3

Functions: Plays a role in the regulation of microglia polarization

The "TAFA3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TAFA3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets